| . | Geographical region . | Income . | |||||||
|---|---|---|---|---|---|---|---|---|---|
| . | All participants . | Europe and Central Asia . | North America . | Latin America . | East Asia and Pacific . | South Asia . | Middle East and Africa . | High- income countries . | Low- and middle- income countries . |
| Management of referrals | |||||||||
| GPs can discuss patients prior to referral, n (%) | 579 (64) | 260 (81) | 61 (79) | 67 (46) | 45 (78) | 32 (57) | 114 (47) | 359 (78) | 220 (50) |
| Referred patients seen by rheumatologist (%), median (IQR) | 100 (80–100) | 100 (90–100) | 100 (100–100) | 100 (90–100) | 100 (100–100) | 100 (80–100) | 90 (10–100) | 100 (95–100) | 100 (20–100) |
| Evaluation of suspected new PMR patients >2 weeks after referral, n (%) | 348 (39) | 127 (40) | 57 (75) | 86 (59) | 30 (53) | 3 (6) | 43 (18) | 234 (51) | 117 (27) |
| Evaluation of suspected new PMR patients >4 weeks after referral, n (%) | 166 (19) | 63 (20) | 18 (24) | 48 (33) | 14 (24) | 1 (2) | 24 (10) | 106 (23) | 61 (14) |
| Referred patients with established PMR diagnosis (%), median (IQR) | 20 (3–50) | 30 (10–50) | 37 (10–55) | 10 (1–50) | 50 (15–70) | 10 (0–25) | 5 (0–25) | 30 (10–50) | 5 (0-33) |
| Diagnosis changed upon evaluation of patients with established PMR diagnosis (%), median (IQR) | 15 (5–30) | 15 (10–30) | 20 (10–45) | 10 (0–50) | 20 (15–40) | 20 (0–50) | 10 (0–30) | 20 (10–30) | 10 (0–30) |
| Prednisolone | |||||||||
| Started prior to evaluation (%), median (IQR) | 50 (15–75) | 50 (30–80) | 60 (50–80) | 50 (10–60) | 55 (30–90) | 50 (10–60) | 25 (5–50) | 50 (30–80) | 30 (5–50) |
| Initial dose (mg), median (IQR) | 20 (15–20) | 16 (15–20) | 20 (15–20) | 20 (15–30) | 15 (15–15) | 20 (15–30) | 20 (15–30) | 15 (15–20) | 20 (15–30) |
| Initial dose > 25 mg, n (%) | 216 (23) | 34 (10) | 5 (6) | 47 (31) | 0 (0) | 20 (35) | 110 (41) | 4 (8) | 178 (38) |
| Duration of treatment (months), median (IQR) | 12 (6–18) | 12 (12–18) | 12 (10–18) | 10 (6–12) | 15 (12–18) | 11 (6–12) | 6 (3–18) | 12 (12–18) | 6 (3–12) |
| Duration of treatment <6 month, n (%) | 133 (14) | 13 (4) | 2 (3) | 35 (23) | 4 (7) | 6 (11) | 72 (27) | 14 (3) | 118 (25) |
| . | Geographical region . | Income . | |||||||
|---|---|---|---|---|---|---|---|---|---|
| . | All participants . | Europe and Central Asia . | North America . | Latin America . | East Asia and Pacific . | South Asia . | Middle East and Africa . | High- income countries . | Low- and middle- income countries . |
| Management of referrals | |||||||||
| GPs can discuss patients prior to referral, n (%) | 579 (64) | 260 (81) | 61 (79) | 67 (46) | 45 (78) | 32 (57) | 114 (47) | 359 (78) | 220 (50) |
| Referred patients seen by rheumatologist (%), median (IQR) | 100 (80–100) | 100 (90–100) | 100 (100–100) | 100 (90–100) | 100 (100–100) | 100 (80–100) | 90 (10–100) | 100 (95–100) | 100 (20–100) |
| Evaluation of suspected new PMR patients >2 weeks after referral, n (%) | 348 (39) | 127 (40) | 57 (75) | 86 (59) | 30 (53) | 3 (6) | 43 (18) | 234 (51) | 117 (27) |
| Evaluation of suspected new PMR patients >4 weeks after referral, n (%) | 166 (19) | 63 (20) | 18 (24) | 48 (33) | 14 (24) | 1 (2) | 24 (10) | 106 (23) | 61 (14) |
| Referred patients with established PMR diagnosis (%), median (IQR) | 20 (3–50) | 30 (10–50) | 37 (10–55) | 10 (1–50) | 50 (15–70) | 10 (0–25) | 5 (0–25) | 30 (10–50) | 5 (0-33) |
| Diagnosis changed upon evaluation of patients with established PMR diagnosis (%), median (IQR) | 15 (5–30) | 15 (10–30) | 20 (10–45) | 10 (0–50) | 20 (15–40) | 20 (0–50) | 10 (0–30) | 20 (10–30) | 10 (0–30) |
| Prednisolone | |||||||||
| Started prior to evaluation (%), median (IQR) | 50 (15–75) | 50 (30–80) | 60 (50–80) | 50 (10–60) | 55 (30–90) | 50 (10–60) | 25 (5–50) | 50 (30–80) | 30 (5–50) |
| Initial dose (mg), median (IQR) | 20 (15–20) | 16 (15–20) | 20 (15–20) | 20 (15–30) | 15 (15–15) | 20 (15–30) | 20 (15–30) | 15 (15–20) | 20 (15–30) |
| Initial dose > 25 mg, n (%) | 216 (23) | 34 (10) | 5 (6) | 47 (31) | 0 (0) | 20 (35) | 110 (41) | 4 (8) | 178 (38) |
| Duration of treatment (months), median (IQR) | 12 (6–18) | 12 (12–18) | 12 (10–18) | 10 (6–12) | 15 (12–18) | 11 (6–12) | 6 (3–18) | 12 (12–18) | 6 (3–12) |
| Duration of treatment <6 month, n (%) | 133 (14) | 13 (4) | 2 (3) | 35 (23) | 4 (7) | 6 (11) | 72 (27) | 14 (3) | 118 (25) |
IQR: interquartile range; GP: general practitioner.
| . | Geographical region . | Income . | |||||||
|---|---|---|---|---|---|---|---|---|---|
| . | All participants . | Europe and Central Asia . | North America . | Latin America . | East Asia and Pacific . | South Asia . | Middle East and Africa . | High- income countries . | Low- and middle- income countries . |
| Management of referrals | |||||||||
| GPs can discuss patients prior to referral, n (%) | 579 (64) | 260 (81) | 61 (79) | 67 (46) | 45 (78) | 32 (57) | 114 (47) | 359 (78) | 220 (50) |
| Referred patients seen by rheumatologist (%), median (IQR) | 100 (80–100) | 100 (90–100) | 100 (100–100) | 100 (90–100) | 100 (100–100) | 100 (80–100) | 90 (10–100) | 100 (95–100) | 100 (20–100) |
| Evaluation of suspected new PMR patients >2 weeks after referral, n (%) | 348 (39) | 127 (40) | 57 (75) | 86 (59) | 30 (53) | 3 (6) | 43 (18) | 234 (51) | 117 (27) |
| Evaluation of suspected new PMR patients >4 weeks after referral, n (%) | 166 (19) | 63 (20) | 18 (24) | 48 (33) | 14 (24) | 1 (2) | 24 (10) | 106 (23) | 61 (14) |
| Referred patients with established PMR diagnosis (%), median (IQR) | 20 (3–50) | 30 (10–50) | 37 (10–55) | 10 (1–50) | 50 (15–70) | 10 (0–25) | 5 (0–25) | 30 (10–50) | 5 (0-33) |
| Diagnosis changed upon evaluation of patients with established PMR diagnosis (%), median (IQR) | 15 (5–30) | 15 (10–30) | 20 (10–45) | 10 (0–50) | 20 (15–40) | 20 (0–50) | 10 (0–30) | 20 (10–30) | 10 (0–30) |
| Prednisolone | |||||||||
| Started prior to evaluation (%), median (IQR) | 50 (15–75) | 50 (30–80) | 60 (50–80) | 50 (10–60) | 55 (30–90) | 50 (10–60) | 25 (5–50) | 50 (30–80) | 30 (5–50) |
| Initial dose (mg), median (IQR) | 20 (15–20) | 16 (15–20) | 20 (15–20) | 20 (15–30) | 15 (15–15) | 20 (15–30) | 20 (15–30) | 15 (15–20) | 20 (15–30) |
| Initial dose > 25 mg, n (%) | 216 (23) | 34 (10) | 5 (6) | 47 (31) | 0 (0) | 20 (35) | 110 (41) | 4 (8) | 178 (38) |
| Duration of treatment (months), median (IQR) | 12 (6–18) | 12 (12–18) | 12 (10–18) | 10 (6–12) | 15 (12–18) | 11 (6–12) | 6 (3–18) | 12 (12–18) | 6 (3–12) |
| Duration of treatment <6 month, n (%) | 133 (14) | 13 (4) | 2 (3) | 35 (23) | 4 (7) | 6 (11) | 72 (27) | 14 (3) | 118 (25) |
| . | Geographical region . | Income . | |||||||
|---|---|---|---|---|---|---|---|---|---|
| . | All participants . | Europe and Central Asia . | North America . | Latin America . | East Asia and Pacific . | South Asia . | Middle East and Africa . | High- income countries . | Low- and middle- income countries . |
| Management of referrals | |||||||||
| GPs can discuss patients prior to referral, n (%) | 579 (64) | 260 (81) | 61 (79) | 67 (46) | 45 (78) | 32 (57) | 114 (47) | 359 (78) | 220 (50) |
| Referred patients seen by rheumatologist (%), median (IQR) | 100 (80–100) | 100 (90–100) | 100 (100–100) | 100 (90–100) | 100 (100–100) | 100 (80–100) | 90 (10–100) | 100 (95–100) | 100 (20–100) |
| Evaluation of suspected new PMR patients >2 weeks after referral, n (%) | 348 (39) | 127 (40) | 57 (75) | 86 (59) | 30 (53) | 3 (6) | 43 (18) | 234 (51) | 117 (27) |
| Evaluation of suspected new PMR patients >4 weeks after referral, n (%) | 166 (19) | 63 (20) | 18 (24) | 48 (33) | 14 (24) | 1 (2) | 24 (10) | 106 (23) | 61 (14) |
| Referred patients with established PMR diagnosis (%), median (IQR) | 20 (3–50) | 30 (10–50) | 37 (10–55) | 10 (1–50) | 50 (15–70) | 10 (0–25) | 5 (0–25) | 30 (10–50) | 5 (0-33) |
| Diagnosis changed upon evaluation of patients with established PMR diagnosis (%), median (IQR) | 15 (5–30) | 15 (10–30) | 20 (10–45) | 10 (0–50) | 20 (15–40) | 20 (0–50) | 10 (0–30) | 20 (10–30) | 10 (0–30) |
| Prednisolone | |||||||||
| Started prior to evaluation (%), median (IQR) | 50 (15–75) | 50 (30–80) | 60 (50–80) | 50 (10–60) | 55 (30–90) | 50 (10–60) | 25 (5–50) | 50 (30–80) | 30 (5–50) |
| Initial dose (mg), median (IQR) | 20 (15–20) | 16 (15–20) | 20 (15–20) | 20 (15–30) | 15 (15–15) | 20 (15–30) | 20 (15–30) | 15 (15–20) | 20 (15–30) |
| Initial dose > 25 mg, n (%) | 216 (23) | 34 (10) | 5 (6) | 47 (31) | 0 (0) | 20 (35) | 110 (41) | 4 (8) | 178 (38) |
| Duration of treatment (months), median (IQR) | 12 (6–18) | 12 (12–18) | 12 (10–18) | 10 (6–12) | 15 (12–18) | 11 (6–12) | 6 (3–18) | 12 (12–18) | 6 (3–12) |
| Duration of treatment <6 month, n (%) | 133 (14) | 13 (4) | 2 (3) | 35 (23) | 4 (7) | 6 (11) | 72 (27) | 14 (3) | 118 (25) |
IQR: interquartile range; GP: general practitioner.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
